Please note: Any medical or genetic information present in this entry is not intended as a diagnosis of your problem, but rather is provided as a helpful guide for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. Information is not necessarily complete. Please see your doctor for diagnosis and treatment.

Please note: DNAtraffic database is the project under construction and information on this page is not finished yet.

Cidofovir


ACCESSION NB: DB00369 (APRD00148)


TYPE: small molecule


GROUP: approved


DESCRIPTION:
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. [Wikipedia]

VOLUME OF DISTRIBUTION: 537 ± 126 mL/kg [VISTIDE ADMINISTERED WITHOUT PROBENECID] 410 ± 102 mL/kg [VISTIDE ADMINISTERED WITH PROBENECID]

CATEGORIES:
Antineoplastic Agents Antiviral Agents Anti-HIV Agents Radiation-Sensitizing Agents

ABSORPTION: 100%

INDICATION:
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

PHARMACODYNAMICS:
Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis.

MECHANISM OF ACTION:
Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.

PROTEIN BINDING:
6%

TOXICITY:
Kidney damage, fall in the number of white blood cells, decreased platelets

AFECTED ORGANISMS:
Human Immunodeficiency Virus